Project Grant R21CA301298
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$414K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $192,489 to the University of Alabama at Birmingham (UAB) from February 1, 2025 to January 31, 2030. The project aims to evaluate the implementation and impact of oncology financial navigation, an evidence-based intervention to help cancer patients manage treatment-related financial hardship. Key activities include: Tracking implementation strategies and their effect on outcomes like...
This Project Grant award of $432,614.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, 17p loss, and NDE1 dependence in cancer cells. The goal is to define the genetic dependencies resulting from these factors and assess the therapeutic potential of targeting NDE1 in cancers with increased chromosomal instability and 17p loss. The award period...
This federal Project Grant award of $156,500, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a study titled "Nurses Surviving Breast Cancer: An Exploration of Breast Cancer Diagnosis, Reported Lymphedema Symptoms, and Lifestyle Status in the Nurses' Health Study Survey". The study aims to 1) explore patterns of incidence of self-reported breast cancer-related lymphedema (BCRL) symptoms, and 2) examine...
The National Cancer Institute awarded a $684,333 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Trustees of Columbia University in the City of New York. The project, titled "Integrating Breast Cancer and Cardiovascular Disease Risk to Explore Decision-Making for Chemoprevention Among Racially/Ethnically Diverse Women at High Risk for Breast Cancer," aims to evaluate if patient and provider decision support that juxtaposes breast cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $182,236 to New York University School of Medicine to adapt and pilot test an evidence-based sexual health communication skills training intervention for prostate cancer patients. The key products and services to be delivered include: Conducting focus groups with prostate cancer patients and interviews with providers to identify barriers and facilitators to patient-provider communication...
The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will support a $734,942 research project over 5 years from August 2025 to July 2030. The research aims to evaluate how biological aging metrics, such as epigenetic clocks and leukocyte composition, are associated with cardiovascular disease (CVD) and mortality risk in breast cancer survivors. The project will...
This $172,197 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to establish and refine processes to facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). Key objectives include: Hiring project navigators to support study approvals for principal investigators in non-oncology departments outside KUCC Training research coordinators in cancer prevention trial processes...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,340 to the University of Miami to support research aimed at identifying epigenetic vulnerabilities in endocrine-resistant breast cancer. The project will investigate the role of the CoREST-SWI/SNF axis in regulating breast cancer cell plasticity and endocrine therapy resistance, focusing on two key resistant settings: breast cancers with ESR1 mutations and those with ARID1A...
This federal Project Grant award, totaling $696,140, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant aims to test a digital psychoeducation-activation tool and implementation strategy, called ICAN DEPCARE, to improve uptake of evidence-based depression treatment among cancer patients. The project, led by The Trustees of Columbia University in the City of New York, will conduct a clinic-level cluster randomized...